Literature DB >> 19923476

Detection of SHV-type extended-spectrum beta-lactamase in Enterobacter isolates.

Trent G Towne1, James S Lewis, Monica Herrera, Brian Wickes, James H Jorgensen.   

Abstract

One hundred four Enterobacter isolates were tested by standard CLSI disk diffusion methods for detecting extended-spectrum beta-lactamases (ESBLs) and with cefepime-clavulanate disk combinations. SHV-12 was produced by 8.7% of isolates. The cefepime-clavulanate combination provided 88% sensitivity and 91% specificity for the detection of SHV-12 ESBL.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19923476      PMCID： PMC2812293          DOI： 10.1128/JCM.01875-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  16 in total

1.  Extended-spectrum beta-lactamases in Enterobacter cloacae: underestimated but clinically significant!

Authors:  B Crowley; G Ratcliffe
Journal:  J Antimicrob Chemother       Date:  2003-03-28       Impact factor: 5.790

Review 2.  The new beta-lactamases.

Authors:  George A Jacoby; Luisa Silvia Munoz-Price
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

3.  Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia.

Authors:  Wonkeun Song; Ellen S Moland; Nancy D Hanson; James S Lewis; James H Jorgensen; Kenneth S Thomson
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

4.  SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae.

Authors:  Dóra Szabó; Robert A Bonomo; Fernanda Silveira; A William Pasculle; Carla Baxter; Peter K Linden; Andrea M Hujer; Kristine M Hujer; Kathleen Deeley; David L Paterson
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases.

Authors:  G A Jacoby; I Carreras
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 6.  Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

Authors:  D L Paterson; W C Ko; A Von Gottberg; J M Casellas; L Mulazimoglu; K P Klugman; R A Bonomo; L B Rice; J G McCormack; V L Yu
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

7.  Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.

Authors:  K S Thomson; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

8.  Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.

Authors:  G Zanetti; F Bally; G Greub; J Garbino; T Kinge; D Lew; J-A Romand; J Bille; D Aymon; L Stratchounski; L Krawczyk; E Rubinstein; M-D Schaller; R Chiolero; M-P Glauser; A Cometta
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  Molecular typing and characterization of extended-spectrum TEM, SHV and CTX-M beta-lactamases in clinical isolates of Enterobacter cloacae.

Authors:  Maurice Biendo; Claudia Manoliu; Geneviève Laurans; Sandrine Castelain; Brigitte Canarelli; Danièle Thomas; Farida Hamdad; Florence Rousseau; François Eb
Journal:  Res Microbiol       Date:  2008-09-19       Impact factor: 3.992

10.  Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology.

Authors:  Anne Marie Queenan; Barbara Foleno; Colleen Gownley; Ellyn Wira; Karen Bush
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948
View more
  6 in total

1.  Method for phenotypic detection of extended-spectrum beta-lactamases in enterobacter species in the routine clinical setting.

Authors:  James Cohen Stuart; Bram Diederen; Nashwan Al Naiemi; Ad Fluit; Niek Arents; Steven Thijsen; Bart Vlaminckx; Johan W Mouton; Maurine Leverstein-van Hall
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

2.  Trends in serotype distribution and antimicrobial susceptibility in Salmonella enterica isolates from humans in Belgium, 2009 to 2013.

Authors:  Pieter-Jan Ceyssens; Wesley Mattheus; Raymond Vanhoof; Sophie Bertrand
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

3.  An Improved Extended-Spectrum-β-Lactamase Detection Test Utilizing Aztreonam plus Clavulanate.

Authors:  Gina K Thomson; Maaz Ayaz; Kelli Lutes; Kenneth S Thomson
Journal:  J Clin Microbiol       Date:  2017-12-26       Impact factor: 5.948

4.  Comparison of different phenotypic assays for the detection of extended-spectrum β-lactamase production by inducible AmpC-producing Gram-negative bacilli.

Authors:  E Willems; R Cartuyvels; K Magerman; M Raymaekers; J Verhaegen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-08       Impact factor: 3.267

5.  Impact of Revised Broad-Spectrum Cephalosporin Clinical and Laboratory Standards Institute Breakpoints on Susceptibility in Enterobacteriaceae Producing AmpC β-Lactamase.

Authors:  Ki Ho Park; Yong Pil Chong; Sung Han Kim; Sang Oh Lee; Mi Suk Lee; Heungsup Sung; Mi Na Kim; Yang Soo Kim; Jun Hee Woo; Sang Ho Choi
Journal:  Infect Chemother       Date:  2017-02-28

6.  ESKAPE Bacteria and Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolated from Wastewater and Process Water from German Poultry Slaughterhouses.

Authors:  Mykhailo Savin; Gabriele Bierbaum; Jens Andre Hammerl; Céline Heinemann; Marijo Parcina; Esther Sib; Alexander Voigt; Judith Kreyenschmidt
Journal:  Appl Environ Microbiol       Date:  2020-04-01       Impact factor: 4.792
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.